You are here

Kadcyla

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

Fierce Pharma

Flag link:

Roche cracks China's ADC market open as Kadcyla scores its first breast cancer OK in the country

Roche cracks China's ADC market open as Kadcyla scores its first breast cancer OK in the country

Endpoints

antibody-drug conjugate

Flag link:

Roche's breast cancer hopes get a boost from post-surgery Kadcyla approval

Roche's breast cancer hopes get a boost from post-surgery Kadcyla approval

Fierce Pharma

HER-2 postive breast cancer

Flag link:

Roche seeks FDA approval for Kadcyla in HER2-positive early breast cancer

Roche seeks FDA approval for Kadcyla in HER2-positive early breast cancer

Pharmaceutical Business Review

HER2-positive early breast cancer

Flag link:

Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help

Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help

Fierce Pharma

BRCA-mutant breast cancer

Flag link:

A Look at Roche’s Potential Revenue Drivers

A Look at Roche’s Potential Revenue Drivers

Market Realist

Flag link:

Inside Roche’s Next Oncology Portfolio Drivers

Inside Roche’s Next Oncology Portfolio Drivers

Yahoo/Market Realist

T-DM1. breast cancer

Flag link:

ImmunoGen, Roche gastric cancer drug fails study

ImmunoGen, Roche gastric cancer drug fails study

Yahoo/Reuters

clinical trials

Flag link:

Large U.S. cancer trial to match genetic glitches to targeted drugs

Large U.S. cancer trial to match genetic glitches to targeted drugs

Yahoo/Reuters

clinical trials

Boehringer Ingelheim

personalized medicine

Flag link:

Roche's Double Drug Failure Is Meaningful

Roche's Double Drug Failure Is Meaningful

Seeking Alpha

Flag link:

Double blow for Roche as breast cancer, Alzheimer's studies fail

Double blow for Roche as breast cancer, Alzheimer's studies fail

Yahoo/Reuters

Alzheimer's disease

Flag link:

Roche Rebuked by U.K. on $152,850 Breast Cancer Drug

Roche Rebuked by U.K. on $152,850 Breast Cancer Drug

Bloomberg

Flag link:

Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla

Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla

Fierce Pharma

Flag link:

Bring out the confetti: 7 of 2013's launches will join Sovaldi, Tecfidera in blockbuster land

Bring out the confetti: 7 of 2013's launches will join Sovaldi, Tecfidera in blockbuster land

Fierce Pharma Marketing

Breo Ellipta and Anoro Ellipta

Flag link:

Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave

Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave

Fierce Pharma Marketing

Flag link:

NICE rejects Roche's hot new breast cancer drug Kadcyla, then invites negotiations

NICE rejects Roche's hot new breast cancer drug Kadcyla, then invites negotiations

Fierce Pharma

HER2-positive metastatic breast cancer

Flag link:

PDL Biopharma: Agreement With Genentech And Roche Is A Net Negative

PDL Biopharma: Agreement With Genentech And Roche Is A Net Negative

Seeking Alpha

Lucentis Xolair

Flag link:

PDL Biopharma says it settled Roche royalty fight

PDL Biopharma says it settled Roche royalty fight

Yahoo/AP

Flag link:

EU backs Roche’s Kadycla in breast cancer

EU backs Roche’s Kadycla in breast cancer

PM Live

Flag link:

7 Disruptive Drugs for the Next Decade

7 Disruptive Drugs for the Next Decade

Motley Fool

Bristol-Myers Squibb

Lexicon Pharmaceuticals

Flag link:

Pages